Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – Peptides containing saccharide radicals – e.g. – bleomycins – etc.
Reexamination Certificate
2007-05-22
2007-05-22
Campbell, Bruce R. (Department: 1654)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
Peptides containing saccharide radicals, e.g., bleomycins, etc.
C514S025000
Reexamination Certificate
active
10070208
ABSTRACT:
The present invention relates to cytostatics which have a tumour-specific action as a result of linkage to αvβ3integrin antagonists via preferred linking units. The preferred linking units guarantee serum stability of the conjugate of cytostatic and αvβ3integrin antagonist and at the same time the desired intracellular action in tumour cells as a result of their enzymatic or hydrolytic cleavability with release of the cytostatic.
REFERENCES:
patent: 4757072 (1988-07-01), Kabbe et al.
patent: 4943579 (1990-07-01), Vishnuvajjala et al.
patent: 4975278 (1990-12-01), Senter et al.
patent: 4980343 (1990-12-01), Stella et al.
patent: 5464796 (1995-11-01), Petersen et al.
patent: 5955100 (1999-09-01), Bosslet et al.
patent: 6271342 (2001-08-01), Lerchen et al.
patent: 0501250 (1992-09-01), None
patent: 0511917 (1992-11-01), None
patent: 0516861 (1992-12-01), None
patent: 0595133 (1994-05-01), None
patent: 8807378 (1988-10-01), None
patent: 9212146 (1992-07-01), None
patent: 9320229 (1993-10-01), None
patent: 9405681 (1994-03-01), None
patent: 9602546 (1996-02-01), None
patent: 9810795 (1998-03-01), None
Brooks et al., “Antiintergrin alpha V beta 3 blocks human breast cancer growth and angiogenesis in human skin” J. Clin Invest, 1995, vol. 96, pp. 1815-1822.
Uhm, J. H., Dooley, N. P., Kyritsis, A. P., Rao, J. S., Gladson, C. L., “Vitronectin, a Glioma-derived Extracellular Matrix Protein, Protects Tumor Cells from Apoptotic Death”, Clinical Cancer Research, 5: 1587-1594 (Jun. 1999).
Damiano, J. S., Cress, A. E., Hazlehurst, L. A., Shtil, A. A., Dalton, W. S., “Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of Integrin and Resistance to Apoptosis in Human Myeloma Cell Lines”, Blood, 93(5): 1658-1667 (Mar. 1999).
Varner, J. A., Cheresh, D. A., “Integrins and Cancer”, Current Opinion in Cell Biology, 8: 724-730 (1996).
Bitan, G., Scheibler, L., Greenberg, Z., Rosenblat, M., Chorev, M., “Mapping the Integrin αvβ3-Ligand Interface by Photoaffinity Cross-Linking”, Biochemistry, 38: 3414-3420 (1999).
Fields, G. B., “Integrins: cell adhesion molecules in cancer”, Exp. Opin. Ther. Patents, 8(6): 633-644 (1998).
Kerr, J. S., “Novel Small Molecule α v Integrin Antagonists: Comparative Anti-Cancer Efficacy with Known Angiogenesis Inhibitors”, Anticancer Research, 19(2A): 959-968 (1999).
Carron, C. P., “A Peptidomimetic Antagonist of the Integrin αvβ3 Inhibits Leydig Cell Tumor Growth and the Development Hypercalcemia of Malignancy”, Cancer Res., 58: 1930-1935 (May 1998).
Nickols, A., “Antiangiogenic and Anticancer Activites of Antagonists of Integrin αvβ3”, Proc. Annu. Meet. AACR., 38(1): 206 (Mar. 1997), Abstract No. 1389.
Macdonald, T. J., “Migration of Human Brain Tumor Cells and Human rain Endothelial Cells on Tenscin Requires the Integrin αvβ3; a Unifying Model for Grain Tumor Invasion and Angiogenesis”, Proc. Annu. Meet., AACR, 39:497 (Mar. 1998), Abstract No. 3382.
Brooks, P. C., “Requirements of Vascular Integrin αvβ3 for Angiogenesis”, Science, 264: 569-571 (Apr. 1994).
Brooks, P. C., “Integrin αvβ3 Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels”, Cell. 79(7): 1157-1164 (Dec. 1994).
Varner, J. A., “Tumor Angiogenesis and The Role of Vascular Cell Integrin αvβ3”, Important Advances in Oncology, pp. 69-87 (1996).
Varner, J. A., “Review: The Integrin αvβ3: Angiogenesis and Apoptosis”, Cell Adhesion and Communication, 3(4):367-374 (1995).
Gasparini, G., “The Rationale and Future Potential of Angiogenesis Inhibitors in Neoplasma”, Drugs. 58(1): 17-38 (Jul. 1999).
Mueller, B. M., “Pre-clinical Therapy of Human Melanoma with Morpholino-doxorubicin Conjugated to a Monoclonal Antibody Directed Against an Integrin on Melanoma Cells”. Antibody, Immunoconjugates, Radiopharm., 4(2): 99-106 (1991).
Sheu Joen, R., “Triflavin, an arg-gly-asp-containing peptide, inhibits the adhesion of tumor cells to matrix proteins via binding to multiple integrin receptors expressed on human hepatoma cells”, Proc. Soc. Exp. Biol. Med., 213(1): 71-79 (1996).
Ashwell, G., Harford, J., “Carbohydrate-Specific Receptors of the Liver”, Ann. Rev. Biochem., 51:531-554 (1982).
Aminoff, D., Bruegge, W., Bell, W., Sarpolis, K., Williams, R., “Role of Sialic Acid in Survival of Erythrocytes in the Circulation: Interaction of Neuraminidase-Treated and Untreated Erythrocytes With Spleen and Liver at the Cellular Level”, Proc. Natl. Acad. Sci. USA, 74: 1521-1524 (Apr. 1977).
Haltiwanger, R., Lehrman, M., Eckhardt, A., Hill, R., “The Distribution and Localization of the Fucose-Binding Lectin in Rat Tissues and the Identification of a High Affinity Form of the Mannose/N-Acetylglucosamine-Binding Lectin in Rat Liver”, J. of Biol. Chem., 261: 7433-7439 (Jun. 1986).
Jansen, R., Molema, G., Ching, T., Oosting, R., Harms, G., Moolenaar, F., Hardonk, M., Meijer, D., “Hepatic Endocytosis of Various Types of Mannose-Terminated Albumins”, J. of Biol. Chem., 266:3343-3348 (Feb., 1991).
Wall, M., Wani, M., Cook, C., Palmer, K., McPhail, A., Sim, G., “Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, A Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca Acuminata”, J. of Am. Chem. Society, 88: 3888-3890 (Aug. 1966).
Brooks, P., Montgomery, A., Rosenfeld, M., Reisfeld, R., Hu, T., Klier. G., Cheresh, D., “Integrin αvβ3Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels”, Cell, 79: 1157-1164 (Dec., 1994).
Brooks, P., Stromblad, S., Klemke, R., Visscher, D., Sarkar, F., Cheresh, D., “Antiintegrin αvβ3Blocks Human Breast Cancer Growth and Angiogenesis in Human Skin”, J. Clin. Invest., 96: 1815-1822 (Oct., 1995).
Fitzpatrick, J., Garnett, M., “Design, Synthesis and In Vitro Testing of Methotrexate Carrier Conjugates Linked Via Oligopeptide Spacers”, Anti-Cancer Drug Design, 10: 1-9 (1995).
Gabius, H., “Endogene Lektine in Tumoren Und Ihre Mogliche Bedeutung Fur Diagnose Und Therapie Von Krebserkrankungen”, Onkologic, 12: 175-181 (Apr. 1989).
Albers Markus
Baumgarten Jörg
Brüggemeier Ulf
Lerchen Hans-Georg
Schoop Andreas
Bayer Aktiengesellschaft
Campbell Bruce R.
Teller Roy
LandOfFree
Integrin-mediated drug targeting does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Integrin-mediated drug targeting, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Integrin-mediated drug targeting will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3744108